Euthymics' Sweet Dreams Could Be Realized With $24MM Series A
This article was originally published in The Pink Sheet Daily
The startup will resume trials on a novel antidepressant lost in the shuffle when DOV Pharmaceuticals ceased operations.
You may also be interested in...
A quarterly report shows an uptick in VC disbursements, but LP commitments are still lagging.
Depression drug won’t be just another “me too” compound, says co-inventor at Mayo Clinic.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.